SIGA Technologies Inc (NASDAQ: SIGA) has announced approximately $13 million in procurement orders for oral TPOXX (tecovirimat) The order includes $11 million for initial procaurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region with an established contract for oral TPOXX. "We expect a portion of the courses of oral TPOXX delivered under these orders will be used to treat active monkeypox cases and represent the first step
Smallpox medicine makers Siga Technologies and Chimerix Inc said on Thursday they had received new orders for their antiviral drugs that are expected to be used as monkeypox treatments amid a global rise in infections. More than 3,000 confirmed cases of monkeypox - which belongs to the family of orthopoxvirus that includes smallpox and cowpox - have been reported from 40 countries where the disease is not endemic. With the numbers rising, the World Health Organization is set to decide on Thursday whether to declare monkeypox a global health emergency.
Orders Received from Two New Jurisdictions, and a Country in the Asia Pacific Region under an Existing ContractNEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $13 million of procurement orders for oral TPOXX (tecovirimat), including $11 million for initial procurement from two new international jurisdictions and an approximate $2 million order